European Journal of Cancer (1965)最新文献_第6页

Studies on the disposition of 2,3-dihydro-1H-imidazo [1,2-b] pyrazole in rodents 2,3-二氢- 1h -咪唑[1,2-b]吡唑在啮齿动物体内的分布研究

European Journal of Cancer (1965) Pub Date : 1981-04-01 DOI: 10.1016/0014-2964(81)90247-4

D.Dale Shoemaker, Ovella C. Ayers, Mary Ellen D'Anna, Richard L. Cysyk

{"title":"Studies on the disposition of 2,3-dihydro-1H-imidazo [1,2-b] pyrazole in rodents","authors":"D.Dale Shoemaker, Ovella C. Ayers, Mary Ellen D'Anna, Richard L. Cysyk","doi":"10.1016/0014-2964(81)90247-4","DOIUrl":"10.1016/0014-2964(81)90247-4","url":null,"abstract":"<div>2,3-Dihydro-1H-imidazo [1,2-b] pyrazole (IMPY, NSC-51143) is a new ribonucleotide reductase inhibitor, presently undergoing clinical evaluation, that exhibits prolonged in vivo antitumor activity in experimental animals. Disposition studies were initiated to determine if the prolonged in vivo antitumor activity of IMPY could be explained by its pharmacologic properties. Plasma disappearance curves of radioactivity were biphasic after the i.v. administration of 100, 250 or 500 mg/kg to rats and 250 mg/kg to mice. The distribution phase was rapid in each case (<math><mtext>t</mtext><msub><mi></mi><mn><mtext>1</mtext><mtext>2</mtext></mn></msub></math> of approximately 30 min or less), followed by a prolonged elimination phase. Radioactivity was distributed to all tissues of rats and mice including brain after an i.v. dose of 250 mg/kg. In rats, 67.8% of the administered radioactivity was excreted in the urine during the first 24 hr. By 120 hr 74.3% had been excreted via the urine compared with 11.1% in the fees, the latter by biliary excretion. The chromatographic profile of the urine collected from rats and mice 4 hr after drug administration indicated extensive metabolism. Thus, the prolonged plasma and tissue levels of parent IMPY and its metabolites can account for the prolonged duration of cytotoxic activity in vivo.</div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 4","pages":"Pages 391-396"},"PeriodicalIF":0.0,"publicationDate":"1981-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90247-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18320788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Appearance of iron free hyperplastic hepatocytes following ferric nitrilotriacetate and 2-acetaminofluorene sequential administration 硝酸三乙酸铁和2-乙酰氨基芴序贯给药后无铁增生肝细胞的外观

European Journal of Cancer (1965) Pub Date : 1981-04-01 DOI: 10.1016/0014-2964(81)90259-0

Gino Malvaldi

引用次数: 6

Phase II evaluation of chlorozotocin (NSC-178248) in advanced human cancer 氯佐菌素(NSC-178248)治疗晚期人类癌症的II期评价

European Journal of Cancer (1965) Pub Date : 1981-03-01 DOI: 10.1016/0014-2964(81)90125-0

Robert W. Talley , Michael K. Samson , Robert W. Brownlee , Ahmad M. Samhouri , Roberto J. Fraile , Laurence H. Baker

{"title":"Phase II evaluation of chlorozotocin (NSC-178248) in advanced human cancer","authors":"Robert W. Talley , Michael K. Samson , Robert W. Brownlee , Ahmad M. Samhouri , Roberto J. Fraile , Laurence H. Baker","doi":"10.1016/0014-2964(81)90125-0","DOIUrl":"10.1016/0014-2964(81)90125-0","url":null,"abstract":"<div>A phase II evaluation of chlorozoticin (CZT), a water soluble nitrosourea, was undertaken to determine its effectiveness and toxicity in a variety of human metastatic neoplasms. The dosage regimen chosen was either 90 or 120 mg/m2 given by i.v. bolus every six weeks. Dosage escalation or de-escalation was dependent on toxicity. There have been 152 patients evaluable for response. The only significant response rates observed were in non-Hodgkin's lymphoma (5/11) and sarcoma (4/27). Single responses were observed in breast and oat cell carcinoma of lung. No responses were observed in melanoma, colorectal, kidney, non-oat cell lung, pancreas, stomach and other carcinomas. Hematological toxicity has been minimal as predicted, but does appear to be cumulative. The major G.I. toxicity has been nausea and vomiting—usually controllable. Occasional hepatic enzyme elevations were observed, and azotemia was observed in 6 patients. Both were reversible. Rare skin and occasional CNS reactions were also seen.</div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 3","pages":"Pages 337-343"},"PeriodicalIF":0.0,"publicationDate":"1981-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90125-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17514362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

The effect of liposome (phospholipid vesicle) entrapment of actinomycin D and methotrexate on the in vivo treatment of sensitive and resistant solid murine tumours 脂质体(磷脂囊)包裹放线菌素D和甲氨蝶呤在体内治疗敏感和耐药实体小鼠肿瘤中的作用

European Journal of Cancer (1965) Pub Date : 1981-03-01 DOI: 10.1016/0014-2964(81)90119-5

S.B. Kaye , Joan A. Boden , Brenda E. Ryman

{"title":"The effect of liposome (phospholipid vesicle) entrapment of actinomycin D and methotrexate on the in vivo treatment of sensitive and resistant solid murine tumours","authors":"S.B. Kaye , Joan A. Boden , Brenda E. Ryman","doi":"10.1016/0014-2964(81)90119-5","DOIUrl":"10.1016/0014-2964(81)90119-5","url":null,"abstract":"<div>When tested in mice bearing the Ridgway osteosarcoma (ROS) the activity of methotrexate entrapped in small cationic liposomes was increased, both in terms of tumour growth inhibition and toxicity for normal tissues. Conversely, actinomycin D entrapped in small cationic liposomes lost its cytotoxic activity, both against the tumor and normal tissues. In addition, liposome-entrapped actinomycin D proved ineffective therapeutically against a new ROS tumour subline in which resistance to free drug had been derived in vivo; moreover, this resistance appeared to have resulted from failure to retain drug rather than through impaired drug uptake. These results, and those obtained from tissue distribution studies using free and liposome-entrapped actinomycin D, suggested that (a) liposome entrapment modifies the pharmacokinetics and hence activity of these drugs by acting as a slow release system rather than by providing a means of selective delivery to tumours, and (b) the use of liposome-entrapped actinomycin D to overcome drug resistance acquired in vivo may be inappropriate.</div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 3","pages":"Pages 279-289"},"PeriodicalIF":0.0,"publicationDate":"1981-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90119-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17993081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 28

Vincristine and bleomycin do not interfere with infusional plasma levels of methotrexate 长春新碱和博来霉素不干扰输注血浆甲氨蝶呤水平

European Journal of Cancer (1965) Pub Date : 1981-03-01 DOI: 10.1016/0014-2964(81)90129-8

L. Ottolenghi , E. Piazza , S. Marsoni , A. Trabattoni , N. Natale , M. Recchia , L. Morasca

引用次数: 1

Histologic subtypes of small cell carcinoma of the lung: Response to therapy 肺小细胞癌的组织学亚型:对治疗的反应

European Journal of Cancer (1965) Pub Date : 1981-03-01 DOI: 10.1016/0014-2964(81)90127-4

Stephen Davis , Harold Sobel

引用次数: 4

Immunological characterization of cell lines established from malignant and normal human urothelium 恶性和正常人尿路上皮细胞系的免疫学特性

European Journal of Cancer (1965) Pub Date : 1981-03-01 DOI: 10.1016/0014-2964(81)90123-7

M. Vilien , H. Wolf , F. Rasmussen

{"title":"Immunological characterization of cell lines established from malignant and normal human urothelium","authors":"M. Vilien , H. Wolf , F. Rasmussen","doi":"10.1016/0014-2964(81)90123-7","DOIUrl":"https://doi.org/10.1016/0014-2964(81)90123-7","url":null,"abstract":"<div>Cell lines from normal or malignant human urothelium, described elsewhere by morphological, cell kinetic and genotypical criteria, have been characterized further by their response to antibody or lymphocyte mediated cytotoxicity in vitro. Four groups of cell lines were included: (1) two fast proliferating cell lines from normal urothelium, (2) three fast proliferating cell lines from transitional cell carcinoma (TCC) together with two transformed sublines of normal derived cell lines, (3) six slowly proliferating TCC lines, and (4) a line from squamous cell carcinoma. HLA antigen expression was demonstrated in the cell lines of groups 1 and 3, but not in lines from group 2 or 4. The sensitivity to spontaneous lymphocyte mediated cytotoxicity (SLMC) of cells in group 1 and 2 exceeded that of cells from group 3 by a factor of 8. The TCC line, HU 456, was more susceptible to SLMC than T 24. Specifically increased cytotoxicity of lymphocytes from patients suffering from interstitial cystitis (IC) against HU 609 from normal urothelium indicated that this line expresses tissue specific antigens, and at the same time that an immune reaction may be part of the pathogenesis of IC. By a sensitive test for antibody-dependent, cell-mediated cytotoxicity (ADCC) antibody activity against HU 456 was found in only one of nine TCC patients and none of five clinical controls. A pronounced non-disease-related blocking serum activity, frequently found, may account for some of the negative findings. The SLMC against HU 456 could be inhibited but not abolished by Fab fragments of rabbit anti-human immunoglobulin, indicating an ADCC mechanism as part of the SLMC.</div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 3","pages":"Pages 321-327"},"PeriodicalIF":0.0,"publicationDate":"1981-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90123-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72069645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Third European organization for research on treatment of cancer-national cancer institute symposium on new drugs in cancer therapy 第三届欧洲癌症治疗研究组织-癌症研究所癌症治疗新药研讨会

European Journal of Cancer (1965) Pub Date : 1981-03-01 DOI: 10.1016/0014-2964(81)90132-8

引用次数: 0

Dr. Joseph P. Geraci's letter to the editor Joseph P.Geraci博士给编辑的信

European Journal of Cancer (1965) Pub Date : 1981-03-01 DOI: 10.1016/0014-2964(81)90131-6

K. Breur, G.W. Barendsen, J.J. Broerse

引用次数: 0

Preoperative chemotherapy for operable solid tumours 可手术实体瘤的术前化疗

European Journal of Cancer (1965) Pub Date : 1981-03-01 DOI: 10.1016/0014-2964(81)90117-1

Anaxagoras N. Papaioannou

引用次数: 21